Outcomes in Black Patients With Early Breast Cancer Treated With Breast Conservation Therapy
Background The race-specific impact of prognostic variables for early breast cancer is unknown for black patients undergoing breast conservation. Methods and Materials This was a retrospective study of 1,231 consecutive patients ≥40 years of age with Stage I–II invasive breast cancer treated with lu...
Gespeichert in:
Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2011-02, Vol.79 (2), p.392-399 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 399 |
---|---|
container_issue | 2 |
container_start_page | 392 |
container_title | International journal of radiation oncology, biology, physics |
container_volume | 79 |
creator | Nichols, Michael A., M.D, Ph.D Mell, Loren K., M.D Hasselle, Michael D., M.D Karrison, Theodore G., Ph.D MacDermed, Dhara, M.D Meriwether, Amber, B.A Witt, Mary Ellyn, R.N Weichselbaum, Ralph R., M.D Chmura, Steven J., M.D., Ph.D |
description | Background The race-specific impact of prognostic variables for early breast cancer is unknown for black patients undergoing breast conservation. Methods and Materials This was a retrospective study of 1,231 consecutive patients ≥40 years of age with Stage I–II invasive breast cancer treated with lumpectomy and radiation therapy at the University of Chicago Hospitals and affiliates between 1986 and 2004. Patients were classified as either black or nonblack. Cox proportional hazards regression was used to model the effects of known prognostic factors and interactions with race. Results Median follow-up for surviving patients was 82 months. Thirty-four percent of patients were black, and 66% were nonblack (Caucasian, Hispanic, and Asian). Black patients had a poorer 10-year overall survival (64.6% vs. 80.8%; adjusted hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.23–2.06) and 10-year disease-free survival (58.1% vs. 75.4%; HR 1.49; 95% CI, 1.18–1.89) compared with nonblack patients. Tumor sizes were similar between nonblack and black patients with mammographically detected tumors (1.29 cm vs. 1.20 cm, p = 0.20, respectively). Tumor size was significantly associated with overall survival (HR 1.48; 95% CI, 1.12–1.96) in black patients with mammographically detected tumors but not in nonblack patients (HR 1.09; 95% CI, 0.78–1.53), suggesting that survival in black patients depends more strongly on tumor size in this subgroup. Tests for race-size method of detection interactions were statistically significant for overall survival ( p = 0.049), locoregional control ( p = 0.036), and distant control ( p = 0.032) and borderline significant for disease-free survival ( p = 0.067). Conclusion Despite detection at comparable sizes, the prognostic effect of tumor size in patients with mammographically detected tumors is greater for black than in nonblack patients. |
doi_str_mv | 10.1016/j.ijrobp.2009.11.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21491576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301609035500</els_id><sourcerecordid>822364327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-d34f3f086549e1ff470404d3fdd39e346a0b55db1cfc215ecad23d7e8d97ae663</originalsourceid><addsrcrecordid>eNqFkltrFDEUgIModq3-A5EBEZ9mPJlkbi-CXdoqFCq4og9CyCZn2Exnk22SKey_N8NsFXzxKYR85_blEPKaQkGB1h-GwgzebQ9FCdAVlBZAmydkRdumy1lV_XxKVsBqyFmCz8iLEAYAoLThz8lZCZzxlncr8ut2isrtMWTGZhejVHfZVxkN2hiyHybuskvpx2N24VGGmK2lVeizTbpF1Avw-ORsQP-QYp3NNjv08nB8SZ71cgz46nSek-9Xl5v15_zm9vrL-tNNrnjDY64Z71kPbV3xDmnf8wY4cM16rVmHjNcStlWlt1T1qqQVKqlLphtsdddIrGt2Tt4ueV2IRgRlIqqdctaiiqKkvKNVM1PvF-rg3f2EIYq9CQrHUVp0UxBtWbKas7JJJF9I5V0IHntx8GYv_VFQELN8MYhFvpjlC0pFkp_C3pwKTNs96j9Bj7YT8O4EyKDk2Puk04S_HGsrVrMqcR8XDpO0B4N-ngmTem38PJJ25n-d_JtAjcaaVPMOjxgGN3mbPkRQEUoB4tu8KPOeQAdpdQDYb4k0uMY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>822364327</pqid></control><display><type>article</type><title>Outcomes in Black Patients With Early Breast Cancer Treated With Breast Conservation Therapy</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Nichols, Michael A., M.D, Ph.D ; Mell, Loren K., M.D ; Hasselle, Michael D., M.D ; Karrison, Theodore G., Ph.D ; MacDermed, Dhara, M.D ; Meriwether, Amber, B.A ; Witt, Mary Ellyn, R.N ; Weichselbaum, Ralph R., M.D ; Chmura, Steven J., M.D., Ph.D</creator><creatorcontrib>Nichols, Michael A., M.D, Ph.D ; Mell, Loren K., M.D ; Hasselle, Michael D., M.D ; Karrison, Theodore G., Ph.D ; MacDermed, Dhara, M.D ; Meriwether, Amber, B.A ; Witt, Mary Ellyn, R.N ; Weichselbaum, Ralph R., M.D ; Chmura, Steven J., M.D., Ph.D</creatorcontrib><description>Background The race-specific impact of prognostic variables for early breast cancer is unknown for black patients undergoing breast conservation. Methods and Materials This was a retrospective study of 1,231 consecutive patients ≥40 years of age with Stage I–II invasive breast cancer treated with lumpectomy and radiation therapy at the University of Chicago Hospitals and affiliates between 1986 and 2004. Patients were classified as either black or nonblack. Cox proportional hazards regression was used to model the effects of known prognostic factors and interactions with race. Results Median follow-up for surviving patients was 82 months. Thirty-four percent of patients were black, and 66% were nonblack (Caucasian, Hispanic, and Asian). Black patients had a poorer 10-year overall survival (64.6% vs. 80.8%; adjusted hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.23–2.06) and 10-year disease-free survival (58.1% vs. 75.4%; HR 1.49; 95% CI, 1.18–1.89) compared with nonblack patients. Tumor sizes were similar between nonblack and black patients with mammographically detected tumors (1.29 cm vs. 1.20 cm, p = 0.20, respectively). Tumor size was significantly associated with overall survival (HR 1.48; 95% CI, 1.12–1.96) in black patients with mammographically detected tumors but not in nonblack patients (HR 1.09; 95% CI, 0.78–1.53), suggesting that survival in black patients depends more strongly on tumor size in this subgroup. Tests for race-size method of detection interactions were statistically significant for overall survival ( p = 0.049), locoregional control ( p = 0.036), and distant control ( p = 0.032) and borderline significant for disease-free survival ( p = 0.067). Conclusion Despite detection at comparable sizes, the prognostic effect of tumor size in patients with mammographically detected tumors is greater for black than in nonblack patients.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2009.11.017</identifier><identifier>PMID: 20434849</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>African Continental Ancestry Group ; Antineoplastic Agents, Hormonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asian Continental Ancestry Group ; Biological and medical sciences ; BODY ; Breast neoplasm ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - ethnology ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Combined Modality Therapy - methods ; Continental population groups ; Disease-Free Survival ; DISEASES ; European Continental Ancestry Group ; Female ; Follow-Up Studies ; Genital system. Mammary gland ; GLANDS ; Gynecology. Andrology. Obstetrics ; Health care ; Hematology, Oncology and Palliative Medicine ; Hispanic Americans ; HUMAN POPULATIONS ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Mammary gland diseases ; MAMMARY GLANDS ; Mammography ; Mastectomy, Segmental ; Medical sciences ; MEDICINE ; Middle Aged ; MINORITY GROUPS ; NEOPLASMS ; NUCLEAR MEDICINE ; ORGANS ; Outcome assessment ; POPULATIONS ; Proportional Hazards Models ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; RADIOLOGY ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy - methods ; Radiotherapy Dosage ; Retrospective Studies ; SIZE ; SURGERY ; SURVIVAL CURVES ; Tamoxifen - therapeutic use ; THERAPY ; Treatment Outcome ; Tumor Burden ; Tumors</subject><ispartof>International journal of radiation oncology, biology, physics, 2011-02, Vol.79 (2), p.392-399</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-d34f3f086549e1ff470404d3fdd39e346a0b55db1cfc215ecad23d7e8d97ae663</citedby><cites>FETCH-LOGICAL-c474t-d34f3f086549e1ff470404d3fdd39e346a0b55db1cfc215ecad23d7e8d97ae663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2009.11.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23853635$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20434849$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21491576$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Nichols, Michael A., M.D, Ph.D</creatorcontrib><creatorcontrib>Mell, Loren K., M.D</creatorcontrib><creatorcontrib>Hasselle, Michael D., M.D</creatorcontrib><creatorcontrib>Karrison, Theodore G., Ph.D</creatorcontrib><creatorcontrib>MacDermed, Dhara, M.D</creatorcontrib><creatorcontrib>Meriwether, Amber, B.A</creatorcontrib><creatorcontrib>Witt, Mary Ellyn, R.N</creatorcontrib><creatorcontrib>Weichselbaum, Ralph R., M.D</creatorcontrib><creatorcontrib>Chmura, Steven J., M.D., Ph.D</creatorcontrib><title>Outcomes in Black Patients With Early Breast Cancer Treated With Breast Conservation Therapy</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Background The race-specific impact of prognostic variables for early breast cancer is unknown for black patients undergoing breast conservation. Methods and Materials This was a retrospective study of 1,231 consecutive patients ≥40 years of age with Stage I–II invasive breast cancer treated with lumpectomy and radiation therapy at the University of Chicago Hospitals and affiliates between 1986 and 2004. Patients were classified as either black or nonblack. Cox proportional hazards regression was used to model the effects of known prognostic factors and interactions with race. Results Median follow-up for surviving patients was 82 months. Thirty-four percent of patients were black, and 66% were nonblack (Caucasian, Hispanic, and Asian). Black patients had a poorer 10-year overall survival (64.6% vs. 80.8%; adjusted hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.23–2.06) and 10-year disease-free survival (58.1% vs. 75.4%; HR 1.49; 95% CI, 1.18–1.89) compared with nonblack patients. Tumor sizes were similar between nonblack and black patients with mammographically detected tumors (1.29 cm vs. 1.20 cm, p = 0.20, respectively). Tumor size was significantly associated with overall survival (HR 1.48; 95% CI, 1.12–1.96) in black patients with mammographically detected tumors but not in nonblack patients (HR 1.09; 95% CI, 0.78–1.53), suggesting that survival in black patients depends more strongly on tumor size in this subgroup. Tests for race-size method of detection interactions were statistically significant for overall survival ( p = 0.049), locoregional control ( p = 0.036), and distant control ( p = 0.032) and borderline significant for disease-free survival ( p = 0.067). Conclusion Despite detection at comparable sizes, the prognostic effect of tumor size in patients with mammographically detected tumors is greater for black than in nonblack patients.</description><subject>African Continental Ancestry Group</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asian Continental Ancestry Group</subject><subject>Biological and medical sciences</subject><subject>BODY</subject><subject>Breast neoplasm</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - ethnology</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Combined Modality Therapy - methods</subject><subject>Continental population groups</subject><subject>Disease-Free Survival</subject><subject>DISEASES</subject><subject>European Continental Ancestry Group</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genital system. Mammary gland</subject><subject>GLANDS</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health care</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hispanic Americans</subject><subject>HUMAN POPULATIONS</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Mammary gland diseases</subject><subject>MAMMARY GLANDS</subject><subject>Mammography</subject><subject>Mastectomy, Segmental</subject><subject>Medical sciences</subject><subject>MEDICINE</subject><subject>Middle Aged</subject><subject>MINORITY GROUPS</subject><subject>NEOPLASMS</subject><subject>NUCLEAR MEDICINE</subject><subject>ORGANS</subject><subject>Outcome assessment</subject><subject>POPULATIONS</subject><subject>Proportional Hazards Models</subject><subject>Radiodiagnosis. Nmr imagery. Nmr spectrometry</subject><subject>RADIOLOGY</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy - methods</subject><subject>Radiotherapy Dosage</subject><subject>Retrospective Studies</subject><subject>SIZE</subject><subject>SURGERY</subject><subject>SURVIVAL CURVES</subject><subject>Tamoxifen - therapeutic use</subject><subject>THERAPY</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><subject>Tumors</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkltrFDEUgIModq3-A5EBEZ9mPJlkbi-CXdoqFCq4og9CyCZn2Exnk22SKey_N8NsFXzxKYR85_blEPKaQkGB1h-GwgzebQ9FCdAVlBZAmydkRdumy1lV_XxKVsBqyFmCz8iLEAYAoLThz8lZCZzxlncr8ut2isrtMWTGZhejVHfZVxkN2hiyHybuskvpx2N24VGGmK2lVeizTbpF1Avw-ORsQP-QYp3NNjv08nB8SZ71cgz46nSek-9Xl5v15_zm9vrL-tNNrnjDY64Z71kPbV3xDmnf8wY4cM16rVmHjNcStlWlt1T1qqQVKqlLphtsdddIrGt2Tt4ueV2IRgRlIqqdctaiiqKkvKNVM1PvF-rg3f2EIYq9CQrHUVp0UxBtWbKas7JJJF9I5V0IHntx8GYv_VFQELN8MYhFvpjlC0pFkp_C3pwKTNs96j9Bj7YT8O4EyKDk2Puk04S_HGsrVrMqcR8XDpO0B4N-ngmTem38PJJ25n-d_JtAjcaaVPMOjxgGN3mbPkRQEUoB4tu8KPOeQAdpdQDYb4k0uMY</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Nichols, Michael A., M.D, Ph.D</creator><creator>Mell, Loren K., M.D</creator><creator>Hasselle, Michael D., M.D</creator><creator>Karrison, Theodore G., Ph.D</creator><creator>MacDermed, Dhara, M.D</creator><creator>Meriwether, Amber, B.A</creator><creator>Witt, Mary Ellyn, R.N</creator><creator>Weichselbaum, Ralph R., M.D</creator><creator>Chmura, Steven J., M.D., Ph.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20110201</creationdate><title>Outcomes in Black Patients With Early Breast Cancer Treated With Breast Conservation Therapy</title><author>Nichols, Michael A., M.D, Ph.D ; Mell, Loren K., M.D ; Hasselle, Michael D., M.D ; Karrison, Theodore G., Ph.D ; MacDermed, Dhara, M.D ; Meriwether, Amber, B.A ; Witt, Mary Ellyn, R.N ; Weichselbaum, Ralph R., M.D ; Chmura, Steven J., M.D., Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-d34f3f086549e1ff470404d3fdd39e346a0b55db1cfc215ecad23d7e8d97ae663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>African Continental Ancestry Group</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asian Continental Ancestry Group</topic><topic>Biological and medical sciences</topic><topic>BODY</topic><topic>Breast neoplasm</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - ethnology</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Combined Modality Therapy - methods</topic><topic>Continental population groups</topic><topic>Disease-Free Survival</topic><topic>DISEASES</topic><topic>European Continental Ancestry Group</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genital system. Mammary gland</topic><topic>GLANDS</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health care</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hispanic Americans</topic><topic>HUMAN POPULATIONS</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Mammary gland diseases</topic><topic>MAMMARY GLANDS</topic><topic>Mammography</topic><topic>Mastectomy, Segmental</topic><topic>Medical sciences</topic><topic>MEDICINE</topic><topic>Middle Aged</topic><topic>MINORITY GROUPS</topic><topic>NEOPLASMS</topic><topic>NUCLEAR MEDICINE</topic><topic>ORGANS</topic><topic>Outcome assessment</topic><topic>POPULATIONS</topic><topic>Proportional Hazards Models</topic><topic>Radiodiagnosis. Nmr imagery. Nmr spectrometry</topic><topic>RADIOLOGY</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy - methods</topic><topic>Radiotherapy Dosage</topic><topic>Retrospective Studies</topic><topic>SIZE</topic><topic>SURGERY</topic><topic>SURVIVAL CURVES</topic><topic>Tamoxifen - therapeutic use</topic><topic>THERAPY</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nichols, Michael A., M.D, Ph.D</creatorcontrib><creatorcontrib>Mell, Loren K., M.D</creatorcontrib><creatorcontrib>Hasselle, Michael D., M.D</creatorcontrib><creatorcontrib>Karrison, Theodore G., Ph.D</creatorcontrib><creatorcontrib>MacDermed, Dhara, M.D</creatorcontrib><creatorcontrib>Meriwether, Amber, B.A</creatorcontrib><creatorcontrib>Witt, Mary Ellyn, R.N</creatorcontrib><creatorcontrib>Weichselbaum, Ralph R., M.D</creatorcontrib><creatorcontrib>Chmura, Steven J., M.D., Ph.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nichols, Michael A., M.D, Ph.D</au><au>Mell, Loren K., M.D</au><au>Hasselle, Michael D., M.D</au><au>Karrison, Theodore G., Ph.D</au><au>MacDermed, Dhara, M.D</au><au>Meriwether, Amber, B.A</au><au>Witt, Mary Ellyn, R.N</au><au>Weichselbaum, Ralph R., M.D</au><au>Chmura, Steven J., M.D., Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes in Black Patients With Early Breast Cancer Treated With Breast Conservation Therapy</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>79</volume><issue>2</issue><spage>392</spage><epage>399</epage><pages>392-399</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Background The race-specific impact of prognostic variables for early breast cancer is unknown for black patients undergoing breast conservation. Methods and Materials This was a retrospective study of 1,231 consecutive patients ≥40 years of age with Stage I–II invasive breast cancer treated with lumpectomy and radiation therapy at the University of Chicago Hospitals and affiliates between 1986 and 2004. Patients were classified as either black or nonblack. Cox proportional hazards regression was used to model the effects of known prognostic factors and interactions with race. Results Median follow-up for surviving patients was 82 months. Thirty-four percent of patients were black, and 66% were nonblack (Caucasian, Hispanic, and Asian). Black patients had a poorer 10-year overall survival (64.6% vs. 80.8%; adjusted hazard ratio [HR], 1.59; 95% confidence interval [CI], 1.23–2.06) and 10-year disease-free survival (58.1% vs. 75.4%; HR 1.49; 95% CI, 1.18–1.89) compared with nonblack patients. Tumor sizes were similar between nonblack and black patients with mammographically detected tumors (1.29 cm vs. 1.20 cm, p = 0.20, respectively). Tumor size was significantly associated with overall survival (HR 1.48; 95% CI, 1.12–1.96) in black patients with mammographically detected tumors but not in nonblack patients (HR 1.09; 95% CI, 0.78–1.53), suggesting that survival in black patients depends more strongly on tumor size in this subgroup. Tests for race-size method of detection interactions were statistically significant for overall survival ( p = 0.049), locoregional control ( p = 0.036), and distant control ( p = 0.032) and borderline significant for disease-free survival ( p = 0.067). Conclusion Despite detection at comparable sizes, the prognostic effect of tumor size in patients with mammographically detected tumors is greater for black than in nonblack patients.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>20434849</pmid><doi>10.1016/j.ijrobp.2009.11.017</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0360-3016 |
ispartof | International journal of radiation oncology, biology, physics, 2011-02, Vol.79 (2), p.392-399 |
issn | 0360-3016 1879-355X |
language | eng |
recordid | cdi_osti_scitechconnect_21491576 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | African Continental Ancestry Group Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Biological and medical sciences BODY Breast neoplasm Breast Neoplasms - diagnostic imaging Breast Neoplasms - ethnology Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Combined Modality Therapy - methods Continental population groups Disease-Free Survival DISEASES European Continental Ancestry Group Female Follow-Up Studies Genital system. Mammary gland GLANDS Gynecology. Andrology. Obstetrics Health care Hematology, Oncology and Palliative Medicine Hispanic Americans HUMAN POPULATIONS Humans Investigative techniques, diagnostic techniques (general aspects) Mammary gland diseases MAMMARY GLANDS Mammography Mastectomy, Segmental Medical sciences MEDICINE Middle Aged MINORITY GROUPS NEOPLASMS NUCLEAR MEDICINE ORGANS Outcome assessment POPULATIONS Proportional Hazards Models Radiodiagnosis. Nmr imagery. Nmr spectrometry RADIOLOGY RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy - methods Radiotherapy Dosage Retrospective Studies SIZE SURGERY SURVIVAL CURVES Tamoxifen - therapeutic use THERAPY Treatment Outcome Tumor Burden Tumors |
title | Outcomes in Black Patients With Early Breast Cancer Treated With Breast Conservation Therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T18%3A42%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20in%20Black%20Patients%20With%20Early%20Breast%20Cancer%20Treated%20With%20Breast%20Conservation%20Therapy&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Nichols,%20Michael%20A.,%20M.D,%20Ph.D&rft.date=2011-02-01&rft.volume=79&rft.issue=2&rft.spage=392&rft.epage=399&rft.pages=392-399&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2009.11.017&rft_dat=%3Cproquest_osti_%3E822364327%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=822364327&rft_id=info:pmid/20434849&rft_els_id=S0360301609035500&rfr_iscdi=true |